During Wednesday’s Morning trade, Shares of Juno Therapeutics Inc. (NASDAQ:JUNO), gained 2.68% to $54.76.
Celgene Corporation, and Juno Therapeutics, declared a global partnership for the development and commercialization of immunotherapies. The two companies will leverage T cell therapeutic strategies to develop treatments for patients with cancer and autoimmune diseases with an initial focus on Chimeric Antigen Receptor Technology (CAR-T) and T Cell Receptor (TCR) technologies.
Under the terms of the collaboration, Celgene has the option to be the commercialization partner for Juno’s oncology and cell therapy auto-immune product candidates, counting Juno’s CD19 and CD22 directed CAR-T product candidates. B-Cell Maturation Antigen (BCMA) is excluded as a target in this collaboration.
Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells. Its clinical stage CD19 product candidates comprise JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL.
Shares of Fiat Chrysler Automobiles N.V. (NYSE:FCAU), inclined 1.72% to $14.78, during its current trading session.
Fiat Chrysler Automobiles, stated U.S. sales of 185,035 units, an 8 percent enhance contrast with sales in June 2014 (171,086 units), and the group’s best June sales since 2006.
The Chrysler, Jeep® and Ram Truck brands each posted year-over-year sales gains in June contrast with the same month a year ago. The Chrysler brand’s 28 percent enhance was the largest sales gain of any FCA US brand during the month. The group extended its streak of year-over-year sales gains to 63-successive months.
“June represented another strong month for our company with sales up 8 percent and our 63rd-successive month of year-over-year sales enhances,” said Reid Bigland, Head of U.S. Sales. “Our all-new Jeep Renegade and Fiat 500X inventory started to arrive at dealerships in greater volume during June positioning us well for the summer-selling season.”
Seven FCA US vehicles set records in the month of June, counting the Chrysler 200, which posted the largest percentage enhance of any FCA US vehicle in the month. Sales of the 200 were up 153 percent, the mid-size sedan’s best June sales ever. The Dodge Journey crossover recorded its best monthly sales ever, while the Jeep Wrangler, Jeep Cherokee, Jeep Patriot, Dodge Challenger and Ram ProMaster each recorded their best June sales ever.
FCA US finished the month of June with a 78-day supply of inventory (577,522 units). U.S. industry sales figures for June are internally projected at an estimated 17.5 million units Seasonally Adjusted Annual Rate (SAAR).
Fiat Chrysler Automobiles N.V., an automotive group, designs, engineers, manufactures, distributes, and sells vehicles and components. It offers passenger cars, light trucks, and light commercial vehicles under the Abarth, Alfa Romeo, Chrysler, Dodge, Fiat, Fiat Professional, Jeep, Lancia, and Ram brand names, in addition to after-sales services and parts under the Mopar brand name.
Finally, Opko Health, Inc. (NYSE:OPK), gained 3.08%, and is now trading at $16.58.
OPKO Health, declared that the Company’s 3.0% Convertible Senior Notes due 2033 (the “Notes”) continue to be convertible by holders of such Notes through September 30, 2015. The Company has elected to satisfy its conversion obligation under the Notes in shares of the Company’s Common Stock.
Wells Fargo Bank, National Association is the trustee for the holders of the Notes and the conversion agent under the Indenture.
OPKO Health, Inc., a biopharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies in the United States and internationally. It operates through two segments, Pharmaceuticals and Diagnostics.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
